MOLMED
MolMed S.p.A. is a medical biotechnology company focused on research, development and clinical validation of novel anticancer therapies. MolMed’s pipeline includes antitumour therapeutics in clinical and preclinical development: Zalmoxis® (TK) is a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression, currently in Phase III in high-risk acute leukaemia and under evaluation by EMA for a Conditional Marketing Auth... orization; NGR-hTNF is a novel therapeutic agent for solid tumours which displays antitumor activity through its specific binding to blood vessels feeding the tumour mass, currently investigated in a broad clinical programme; CAR-CD44v6, an immuno-gene therapy project potentially effective for many haematological malignancies and several epithelial tumours, currently in preclinical development. MolMed also conducts cell and gene therapy projects in collaboration with third parties, offering resources and expertise covering preclinical to Phase III trials activities.
MOLMED
Social Links:
Industry:
Biotechnology
Founded:
1996-01-01
Address:
Bresso, Lombardia, Italy
Country:
Italy
Website Url:
http://www.molmed.com
Total Employee:
101+
Status:
Active
Contact:
+39 0221277.1
Email Addresses:
[email protected]
Total Funding:
15 M EUR
Technology used in webpage:
GoDaddy SSL Apple Whitelist
Similar Organizations
Faze Medicines
Faze Medicines is a biotechnology company.
Idogen
Idogen is a biotechnology company.
Immunicom
Immunicom is a biotechnology company.
KBP Biosciences
A multinational clinical stage biotechnology company.
Laxxon Medical
Laxxon Medical is a biotechnology company.
Neomorph
Neomorph is a biotechnology company.
Themis Bioscience
Themis Bioscience is a start-up biotechnology company.
TikoMed
TikoMed is a biotechnology company.
Current Employees Featured
Founder
Investors List
European Investment Bank
European Investment Bank investment in Debt Financing - MolMed
Official Site Inspections
http://www.molmed.com
- Host name: 93-62-187-14.ip23.fastwebnet.it
- IP address: 93.62.187.14
- Location: Milan Italy
- Latitude: 45.4707
- Longitude: 9.1889
- Timezone: Europe/Rome
- Postal: 20122
More informations about "MolMed"
Home | Molecular Medicine
Molecular Medicine is an open access journal publishing recent findings that elucidate disease pathogenesis at the molecular or physiological level, which may lead to the design of specific …See details»
AGC to Complete the Acquisition of MolMed on July …
(SEATTLE), July 27, 2020 -- AGC Biologics, a Global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced that they will acquire the majority of the share capital of Molecular Medicine S.p.A. …See details»
home | molmed
Nov 19, 2019 · Offerta pubblica di acquisto volontaria totalitaria sulle azioni ordinarie di MolMed S.p.A. comunicata da AGC Inc.. 17 Marzo 2020 - 10:27 Sabato 15/2 Riccardo Palmisano …See details»
MolMed S.p.A Becomes AGC Biologics S.p.A Following the July …
Oct 27, 2020 · AGC Biologics Now Provides End-to-End Cell and Gene Therapy CDMO Services. (SEATTLE), October 27, 2020 -- After its parent company AGC Inc. acquired 100% of the …See details»
home | molmed
Mar 17, 2020 · Tailor made GMP services for viral vector manufacturing and cell engineering. * Please note: this Company presentation has been made before Zalmoxis' CMA withdrawal on …See details»
MolMed - Wikipedia
MOLMED is a biotechnology company founded in 1996 in Milan. It originally operated as contract manufacturing organization and other services for companies developing gene therapy and …See details»
AGC to Complete the Acquisition of MolMed on July …
SEATTLE, July 27, 2020 /PRNewswire/ -- AGC Biologics, a Global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced that they will acquire the majority of...See details»
MolMed - Crunchbase Company Profile & Funding
MolMed S.p.A. is a medical biotechnology company focused on research, development and clinical validation of novel anticancer therapies. MolMed’s pipeline includes antitumour …See details»
MolMed S.p.A Becomes AGC Biologics S.p.A Following the ... - PR …
Oct 27, 2020 · AGC Biologics is now one of the very few CDMO's in the world offering both plasmid production and end-to-end cell and gene therapy services.See details»
AGC to Complete the Acquisition of MolMed on July 31, 2020
SEATTLE, July 27, 2020 /PRNewswire/ -- AGC Biologics, a Global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced that they will acquire …See details»
MolMed S.p.A Becomes AGC Biologics S.p.A Following the July …
Oct 28, 2020 · AGC Biologics is now one of the very few CDMO's in the world offering both plasmid production and end-to-end cell and gene therapy services.See details»
AGC to bolster drug services with MolMed acquisition
Mar 21, 2020 · Aiming to add gene and cell therapy to its drug contract development and manufacturing business, the Japanese glass and chemical firm AGC is buying MolMed, a …See details»
Alira Health as Advisor to AGC Biologics in Acquisition | Alira Health
Aug 20, 2020 · Thanks to the experience and know-how acquired in over 20 years of activity, MolMed is a reference player in the Cell & Gene sector, able to manage all phases of research …See details»
Molecular Medicine - Org Chart, Teams, Culture & Jobs | The Org
MolMed S.p.A. is a clinical-stage biotech company focused on research, development, manufacturing, and clinical validation of innovative therapies. MolMed's product portfolio …See details»
Pipeline | molmed
Sep 30, 2020 · MolMed is a clinical biotech company focused on research, development, manufacturing and clinical validation of innovative therapies in oncology and immuno-oncologySee details»
MolMed Company Profile 2024: Valuation, Investors, Acquisition
Molmed SpA is an Italy based medical biotechnology company. It is engaged in research, development and clinical validation of innovative therapies to treat cancer. The company's …See details»
MolMed Company Profile - Office Locations, Competitors ... - Craft
MolMed is a biotechnology company focused on research, development and clinical validation of novel antitumour therapies.See details»
Articles | Molecular Medicine - BioMed Central
Pulmonary fibrosis (PF) is a progressive and difficult-to-heal lung disease that poses a significant threat to human life and health. This study aimed to investigate the potential pathological …See details»
Italy: EIB supports MolMed investment in research, development …
Dec 18, 2019 · MolMed is a biotech company based in Milan focused on research, development, manufacturing and clinical validation of gene and cell therapies for the treatment of cancer and …See details»
Lycorine ameliorates liver steatosis, oxidative stress, ferroptosis …
1 day ago · Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common liver disease worldwide and few drugs are available for its treatment. Lycorine …See details»